Bioprinting of three-dimensional culture models and organ-on-a-chip systems

Yan Yan Shery Huang, Duo Zhang, and Ye Liu

Multimaterial bioprinting technologies offer promising avenues to create mini-organ models with enhanced tissue heterogeneity and complexity. This article focuses on the application of three-dimensional bioprinting to fabricate organ-on-a-chip systems for *in vitro* drug testing and screening. We illustrate the capabilities and limitations of a bioprinting approach compared to microfabrication in constructing an organ-on-a-chip device. Further, we propose strategies in multimaterial integration for printing microphysiological tissue models. With these analyses, key challenges and future directions are highlighted.

Introduction

In the last decade, we have seen tremendous progress in three-dimensional (3D) cell culture technologies, and the development of culture systems exhibiting more complex cellular interfaces than a conventional flat petri dish.[1,2] These culture systems have been used for landmark developments in mini-organ models, such as organoids with realistic microanatomy,[3] and organ-on-a-chip systems in simulating tissue/organ-level physiology.[4] Combined with advances in stem cell technologies, these culture systems are envisaged to fulfill roles in bridging gaps between preclinical and clinical models in the drug development pipeline, and ultimately, reducing costly failures in clinical trials.[5,6]

While it is important to harness *in vitro* biological models to address specific questions, simple two-dimensional cultures cannot capture many of the key microenvironmental factors (**Table I**) known to influence cell fates. Culturing cells in a complex configuration, however, is labor intensive and costly. Recent advances in bioprinting and biofabrication technologies offer promising new strategies to create tissue scaffolds and tissue models.

Bioprinting can provide the potential capability to repeatedly build small-scale tissue systems, minimizing human intervention and improving standardization and accuracy.[7,8] Second, due to its ability to automate and program the deposition of cells and materials in 3D,[9,10] bioprinting also provides new possibilities to construct a cell niche with prescribed complexity and physiological resemblance. These two general attributes may address some of the critical steps toward the adaption of complex culture systems. These include, for example, the necessity for standardization, validation, and reproducibility, and meeting investigators' desires to create complex co-culture systems with more than four cell types, in a predefined spatial configuration (please see Reference 2 for survey results). The latter attribute may be regarded as the key advantage not easily facilitated by microfabrication and lithography-based approaches.

In this article, direct comparisons between 3D bioprinted and microfabricated organ-on-a-chip models are presented. Further, we propose how a fit-for-purpose bioprinting process can be designed to construct cellular microenvironments for *in vitro* tissue and organ models.

Comparison between bioprinted and microfabricated models

A number of organ- and disease-on-a-chip models have been developed as a result of advanced microfluidic technologies.[1,11] Mini-organ models have been established for various organs, including the lung,[4] heart,[12] kidney,[13] and liver.[14] Simultaneously, disease models such as local cancer invasion

Yan Yan Shery Huang, Department of Engineering, University of Cambridge, UK; yysh2cam@gmail.com
Duo Zhang, Department of Engineering, University of Cambridge, UK; dz301@cam.ac.uk
Ye Liu, Department of Engineering, University of Cambridge, UK; yl558@cam.ac.uk
doi:10.1557/mrs.2017.163

Table I. Reproducing microenvironmental cues using established lithography-based microfluidics and three-dimensional (3D) bioprinting. Comparison of engineering strategies, capabilities, and limitations of both techniques.

Microenvironment Cues to Mimic	Strategies		Capabilities		Limitations	
	Conventional Microfluidics	**3D Printing**	**Conventional Microfluidics**	**3D Printing**	**Conventional Microfluidics**	**3D Printing**
Spatial organization of cells/ECMs	• Encapsulation of cells/ECMs in microcompartments • Porous membranes between adjacent channels	• Encapsulation of cells in ECM-mimicking hydrogels • 3D layer-by-layer deposition	• Reduced material usage	• Image-guided deposition • Spatial combination of multiple cell types and materials	• Surface treatment required to improve PDMS compatibility • Cells/ECMs positioning restricted to specific designs	• Limited resolution and shape fidelity • Difficult to form vasculatures
Chemical gradient and soluble factors	• Fluid stream carrying chemicals of different concentrations	• Gels of varying chemical levels in microfluidic nozzles • Incorporating channel structures	• Precise, spatiotemporal gradients within high-resolution channels	• Chemical gradients in ECM hydrogels	• Gradients restricted to planar configuration	• Multisteps required to form channel structures
Nonflow-related mechanical stimuli	• Use elastic properties of PDMS • Vacuum-controlled mechanical strain	• Applying global force stimuli on post-printed tissues	• PDMS membrane deformation • *In situ* micropumps and valves	• Global deformation in whole tissue	• Limited to the elastic properties of PDMS	• Difficult to generate localized deformation
ECM properties	• Channel coating with ECM components • Inserting hydrogels in microcompartments • 2D micropatterned ECM	• Tuning hydrogel design and composition in 3D	• Reduced material usage • *In situ* cross-linking of gels	• Synthetic hydrogels • Decellularized matrix • Microcarriers	• Surface treatment required to stabilize gel position • Hydrogel localization restricted to specific designs	• Tradeoff between hydrogel robustness and cell viability
Topography	• Computer-aided planar design • Established design elements	• Computer-aided design for layer-by-layer deposition	• Versatile design • Micrometer- to nanoscale resolution	• Combining a wide range of materials with varying biomechanical properties	• Limited to planar structures • Difficult to achieve micro-features with varying heights and curvature	• Feature size limited by the mechanical properties of the substrate • Low resolution
Fluidic circulation	• Established protocols for channel network formation	• Using fugitive inks for channel formation	• Perfusable planar vasculature • Flow-induced shear stress • Long-term culture	• Perfusable 3D vasculature • Flow-induced shear stress • Long-term culture • Facilitation of thick tissue formation	• Difficult to form 3D channel networks	• Biocompatibility and ease of operation of fugitive inks • Demonstrated resolution ~100 µm

Note: ECM, extracellular matrix; PDMS, poly(dimethylsiloxane); 2D, two-dimensional.

and cancer transendothelial migration through the vessel barrier have also been demonstrated.[15] Among these, there are simple systems comprising a simple cell type within a microfluidic channel,[16] to complex designs containing multicellular components coupled with 3D gels and circulation.[17] Huh et al.[18] and Sackmann et al.[19] have summarized the progress to date.

In comparison to the microfabricated platforms, the capability of 3D bioprinting has yet to be extensively exploited, though selected functional tissue and organ models on a chip were recently demonstrated.[8] With the main purpose of re-creating aspects of microenvironmental cues, it is important to identify how a bioprinting approach resembles or differs from a microfabrication approach. Table I lists the main operating mechanisms associated with the respective technique in achieving the desired microenvironmental cues. We further present a side-by-side comparison between similar organ-on-a-chip and screening models generated by the two techniques in **Table II**.[4,12,14,20–31] We highlight the key results shown in the two tables here.

Although both microfluidics and bioprinting allow spatial organization of cells and extracellular matrix gels, the mechanisms facilitating these differ greatly. In microfluidic chips, materials are organized by flow paths in the channels, and therefore, compartmentalization and special flow geometries need to be designed to allow localized cell material seeding.[32,33] On the other hand, 3D printing can provide a more direct deposition approach through the control of nozzle positions.[34] However, in order to create vessel and tubule-like features, both techniques require flow-directed cell-seeding within a channel geometry.[35]

Nonetheless, the convenience of bioprinting to integrate multiple cells, hydrogels, and even sensors has enabled the creation of liver,[23,24] heart,[31] and skin[21,22] models with improved biological functions and read-out abilities than conventional culture systems. For example, Lind et al.,[31] in a recent heart model, reported that soft strain gauge sensors could be directly printed by a multimaterial printer and embedded in a printed cardiac tissue, enabling long-term and facile digital readouts of contractile stresses in the engineered tissue. As a comparison, such one-step integration of on-chip sensors in tissue constructs is difficult to achieve by a microfabrication-based approach. Agarwal et al.[12] developed a heart-on-a-chip system and showed that multistep assembly procedures were required to form the muscular thin film (thin elastic films on which muscle cells can grow) within the chip. Although such a system only has a single-layered configuration, it has benefits of being an autoclavable and reusable device.

As shown in Table II, current bioprinting approaches offer lower planar resolution than microfluidics. For example, the creation of channel features is important for many purposes, including improving long-term cell viability by providing nutrient/waste exchange, imposing flow-induced shear, and incorporating dynamic concentration gradients. Lithography-based templating offers established protocols that facilitate the creation of these microchannel features.[19] In contrast, achieving

channels in bioprinting involves the use of fugitive inks (inks that liquefy when exposed to temperature changes) and intricate ink removal procedures, also accompanied by poorer feature resolution of ~100 μm at the present.[29]

For screening applications, one important practical consideration is the amount of cells and extracellular matrix materials required for forming a tissue model, and also, the quantity of compounds needed for a drug test. So far, processes inherent in low-resolution cell printing lead to larger tissue sizes compared to the microfabricated chip systems; thus, larger quantities of cells and testing compounds, which can often be expensive or sparse, are required. On the other hand, if materials restrictions are not imposed, bioprinting provides the unique capability to create thick tissues by incorporating 3D interconnected channels or vessels for nutrient/waste exchange.[30,36]

As shown in Table II, a recent 3D vasculature printed from fugitive inks by Kolesky et al.[30] was able to support a large bioprinted multicellular tissue (>1 cm in thickness) under long-term perfusion (>6 weeks). In comparison, in established microfluidic chips, although the channel resolution and the resultant vasculature are finer, the cell layout is usually much thinner in the planar fashion (<1 cm in thickness).[28] Therefore, bioprinted thick tissue has advantages in capturing a higher degree of tissue heterogeneity and complexity[37] and possibly providing closer physiological relevance in simulating realistic drug transport from circulation to the targeted tissues.

Finally, non-flow related mechanical stimuli can be seen as one of the most demanding microenvironmental factors to be integrated within a microphysiology device. In soft-lithography-based microfluidics, the majority of the published work has harnessed the deformability of poly(dimethylsiloxane) (PDMS) to form pillars, valves, and stretchable membranes.[12] Huh et al.[4] provide a well-known example in the membrane-based double-layer lung-on-a-chip system. To mimic the mechanical deformation of the lung alveoli during the breathing motion, a vacuum pump was connected to two empty side channels to generate a cyclic stretching motion on the PDMS membrane sandwiched between two layers of microchannels. Such a deformation mechanism imposes stringent demands on the robustness of the materials and device packaging, not yet achievable in a bioprinted construct at the microarchitectural level. Hölzl et al.[38] and Arslan-Yildiz et al.[39] show in their studies how mechanical forces were exerted on the bulk of bioprinted tissues utilizing a separate mechanical rig, which, however, is only viable for larger tissue constructs at a reduced test throughput. Nonetheless, continued improvements in print technology and the potential combination of microfabrication and bioprinting approaches can help address some of these technical challenges.

Material integration for printing microenvironmental cues

The integration among printed cells, extracellular matrices, and a miniature bioreactor can potentially lead to more precise and

Table II. Side-by-side comparison of microengineered tissue/organ models via established microfabrication versus three-dimensional (3D) bioprinting techniques.

Tissue and Organ Model	Established Microfluidics Culture			3D Bioprinting		
	Method	Component	Sample Construct	Method	Component	Sample Construct
Skin	• Membrane-based three-layer microfluidic structure[20]	• Keratinocytes, fibroblasts, endothelial cells[20]	A skin-on-a-chip device with three PDMS layers[20]	• Microvalve DBB[21] •Modified LIFT[22]	• Collagen, fibroblasts, keratinocytes[21,22]	Modified LIFT printed color-layers of keratinocytes[22]
Liver	• Microfluidic gradient generator; compartmentation by pillar arrays[14]	• Rat hepatocytes[14]	Hepatocytes cultured in a chip forming 3D aggregates[14]	• Piezo-electric inkjet DBB[23] • DLP[24]	• Fibronectin, gelatin, hepatocytes[23] • hiPSCs, endothelial and mesenchymal cells, GelMA, GMHA[24]	Patterns of printed hydrogel-based hepatic construct[24]
Brain	• Membrane-based co-culture; embedded electrodes[25]	• Rat endothelial cells, astrocytic cells[25]	Designed μBBB channels model the neurovascular unit[25]	• Piezo-electric inkjet DBB[26]	• Primary cortical neurons, glial cells, RGD modified gellan gum[26]	Handheld reactive printed structure with cortical neurons[26]
Lung	• Membrane-based co-culture; cyclic mechanical strain; air–liquid flow[4]	• Human pulmonary endothelial and alveolar epithelial cells[4]	Microengineered model of human pulmonary edema[4]	• Microvalve DBB[27]	• Alveolar epithelial type II cells, endothelial cells, Matrigel[27]	Two-layer bioprinted co-culture of epithelial cells at day 3[27]
Vasculature	• Lining of predefined microchannels; angiogenesis[28]	• Human endothelial cells[28]	Perfusion of fluorescent microparticles inside vessel lumen[28]	• Microvalve DBB[29] • Pneumatic EBB[30]	• Human lung fibroblasts and endothelial cells, fibrinogen[29] • Human dermal fibroblasts and endothelial cells, hMSCs, gelatin, fibrin[30]	Interpenetrated sacrificial and cell inks as printed on a chip[30]
Heart	• Embedded electrodes, thin-film cantilever for culturing of cells/ECMs[12]	• Rat cardiac myocytes[12]	Operation of the heart-on-a-chip during peak systole[12]	• Pneumatic EBB[31]	• Rat ventricular myocyte, human stem cell-derived cardiomyocyte hiPS-CMs, dextran, PU, Ag, pentanol, PDMS[31]	Automated printing of the device on a glass slide substrate[31]

Note: hMSC, human mesenchymal stem cell; hiPS-CM, human-induced pluripotent stem cell-derived cardiomyocytes; PU, polyurethane; ECM, extracellular matrix; HiPSC, human-induced pluripotent stem cell; μBBB, microfluidic blood–brain barrier; DBB, droplet-based bioprinting; EBB, extrusion-based bioprinting; DLP, digital light processing; LIFT, laser-induced forward transfer; GelMA, gelatin methacryloyl; GMHA, glycidyl methacrylate-hyaluronic acid; RGD, arginine-glycine-aspartic acid; PDMS, poly(dimethylsiloxane).

flexible recreation of the microenvironmental cues *in vitro*. To facilitate such a "bioprinted organ-on-a-chip" device, materials with diverse properties, from natural to synthetic in origin, need to be combined together to perform different roles in the device. **Figure 1** summarizes different materials that have been used in bioprinting (not specific to organ-on-a-chip). The proposed materials functionality can be largely defined as being biologically focused or structurally focused. For example, biologically active hydrogels can provide a matrix for cell encapsulation, cell binding, and a reservoir for growth factor release. The mechanical weakness of the biologically active hydrogels can be potentially overcome by combining with other robust hydrogels, or by designing mechanical supports from thermoplastic or thermoset structures.[40] Examples include the creation of core–shell hydrogel structures between alginate and cell-embedded collagen,[41] and the incorporation of nano- and microfibers[42] within hydrogels. The design of multiwell compartments using PDMS can also be seen as a strategy to provide structural support to the printed bioinks.[37]

The diverse materials properties inevitably require different processing techniques for these materials. This means that print techniques based on direct material dispensing mechanism may find broader applications with their cross-technique compatibility. Based on this concept, a number of commercial bioprinters have already established multinozzle deposition platforms. Ozbolat et al.[9] and Gudapati et al.[10] provide overviews of the different direct deposition printing mechanisms and their material suitability. Regardless of the technique, specific attention must be paid to the mismatched processing parameters between different materials. For example, thermoplastics are normally printed under elevated temperatures in a molten form.[34] However, this processing condition may affect the hydrated biological system if the solidified thermoplastic structure cannot be cooled rapidly. Any solvents or excess

cross-linking reagents contained in the thermoset material can also disturb biological behaviors.[8] Further, it is well known that process-induced thermal, mechanical, or photo stresses can dramatically decrease cellular viability.[43] The processing time (i.e., the duration for which cells are taken out of the incubator environment) needs to be minimized.

Finally, it is worth noting that many of the bioprinted constructs demonstrated so far consist of simple components aimed at musculoskeletal applications that can create robust, macroscopic tissues for implantation.[36] The bioprinting techniques established from these experiences may need to be adjusted for printing soft, complex tissues for organ-on-a-chip devices. Considerations should be given to the self-assembly capability of different cell types; the matrix synthesis and remodeling ability of cells; and also the phase segregation phenomena of different material mixtures. These factors should be accounted for in designing a chip device to accommodate the tissue dynamics over long-term culture.

Conclusion

Advances in bioprinting are accelerating progress toward organ-on-a-chip devices for modeling tissue behaviors with enhanced physiological relevance. Integrating multiple printing techniques, materials, and cells will provide new opportunities for making complex tissue models supporting long-term cultures; but one should be cautious in designing the fabrication strategy to accommodate the processing tolerances for different materials/cells.

Continued developments in this area could bring higher print resolutions, incorporate dynamic mechanical stimulation that better mimic what cells/tissues experience *in vivo*, and integrate optical and electronic materials for *in situ* sensing and activation. Harnessing these functionalities will lead to smart organ-on-a-chip devices for high-content pharmaceutical screening with low-reagent usage. It is important to note that the examples illustrated in this article stem from an engineering technology development prospective. The successful creation and implementation of an *in vitro* model relies heavily on in-depth understanding of the biological pathways and physiological systems; and this will require significant collaborative efforts between engineers and biomedical researchers to fine-tune and optimize the culture conditions. As an intermediate step, 3D bioprinting can be seen as an invaluable toolkit to facilitate easy customization of the culture conditions, enabling systematic evaluation of the different microenvironmental cues (and their combinations) to realize a particular biological phenotype. Like all *in vitro* model systems, for bioprinted organ-on-a-chip to have a real impact on drug development, one should design the level of biological model complexity, corresponding to the stage of the preclinical

Figure 1. Word cloud diagrams illustrating the statistics of literature reports on materials selection, bioprinting parameters, and the bioprinted cells and tissues. The relative size of each word/phrase is an indication of the relative abundance of the reported subject from Scopus and Web of Science (February 2017), in comparison to the other subjects in the same category. The stiffness ranking of the cells as well as tissue and organs are based on their reported *in vivo* native extracellular matrix (ECM)/tissue stiffness. Note: GelMA, gelatin methacryloyl; PLA, polylactic acid; PCL, poly(caprolactone); PEGDA, polyethylene glycol diacrylate; PU, polyurethane; PDMS, poly(dimethylsiloxane); ESC, embryonic stem cell; MSC, mesenchymal stem cell; PEG, poly(ethylene glycol).

testing required. Ongoing system validation, *in vivo–in vitro* correlation, and regulatory approvals should be sought.

Acknowledgments

References

1. S.N. Bhatia, D.E. Ingber, *Nat. Biotechnol.* **32**, 760 (2014).
2. Y. Liu, E. Gill, Y.Y.S. Huang, *Future Sci. OA*, **3** (2), (2017).
3. T. Sato, R.G. Vries, H.J. Snippert, M. Van de Wetering, N. Barker, D.E. Stange, J.H. Van Es, A. Abo, P. Kujala, P.J. Peters, H. Clevers, *Nature* **459**, 262 (2009).
4. D. Huh, D.C. Leslie, B.D. Matthews, J.P. Fraser, S. Jurek, G.A. Hamilton, K.S. Thorneloe, M.A. McAlexander, D.E. Ingber, *Sci. Transl. Med.* **4**, 147 (2012).
5. F. Pampaloni, E.G. Reynaud, E.H. Stelzer, *Nat. Rev. Mol. Cell Biol.* **8**, 839 (2007).
6. E.W. Esch, A. Bahinski, D. Huh, *Nat. Rev. Drug Discov.* **14**, 248 (2015).
7. S.V. Murphy, A. Atala, *Nat. Biotechnol.* **32**, 773 (2014).
8. C. Mandrycky, Z. Wang, K. Kim, D.H. Kim, D.H., *Biotechnol. Adv.* **34**, 422 (2016).
9. I.T. Ozbolat, M. Hospodiuk, *Biomaterials* **76**, 321 (2016).
10. H. Gudapati, M. Dey, I. Ozbolat, *Biomaterials* **102**, 20 (2016).
11. D. Huh, H.J. Kim, J.P. Fraser, D.E. Shea, M. Khan, A. Bahinski, G.A. Hamilton, D.E. Ingber, *Nat. Protoc.* **8**, 2135 (2013).
12. A. Agarwal, J.A. Goss, A. Cho, M.L. McCain, K.K. Parker, *Lab Chip* **13**, 3599 (2013).
13. K.J. Jang, A.P. Mehr, G.A. Hamilton, L.A. McPartlin, S. Chung, K.Y. Suh, D.E. Ingber, *Integr. Biol.* (Camb.) **5**, 1119 (2013).
14. Y.C. Toh, T.C. Lim, D. Tai, G. Xiao, D. van Noort, H. Yu, *Lab Chip* **9**, 2026 (2009).
15. J.S. Jeon, S. Bersini, M. Gilardi, G. Dubini, J.L. Charest, M. Moretti, R.D. Kamm, *Proc. Natl. Acad. Sci.* **112**, 818 (2015).
16. M. Tsai, A. Kita, J. Leach, R. Rounsevell, J.N. Huang, J. Moake, R.E. Ware, D.A. Fletcher, W.A. Lam, *J. Clin. Invest.* **122**, 408 (2012).
17. I. Maschmeyer, A.K. Lorenz, K. Schimek, T. Hasenberg, A.P. Ramme, J. Hübner, M. Lindner, C. Drewell, S. Bauer, A. Thomas, N.S. Sambo, *Lab Chip* **15**, 2688 (2015).
18. D. Huh, G.A. Hamilton, D.E. Ingber, *Trends Cell Biol.* **21**, 745 (2011).
19. E.K. Sackmann, A.L. Fulton, D.J. Beebe, *Nature* **507**, 181 (2014).
20. M. Wufuer, G. Lee, W. Hur, B. Jeon, B.J. Kim, T.H. Choi, S. Lee, *Sci. Rep.* **6**, 37471 (2016).
21. V. Lee, G. Singh, J.P. Trasatti, C. Bjornsson, X. Xu, T.N. Tran, S.S. Yoo, G. Dai, P. Karande, *Tissue Eng. Part C Methods* **20** (6), 473 (2013).
22. L. Koch, A. Deiwick, S. Schlie, S. Michael, M. Gruene, V. Coger, D. Zychlinski, A. Schambach, K. Reimers, P.M. Vogt, B. Chichkov, *Biotechnol. Bioeng.* **109**, 1855 (2012).
23. M. Matsusaki, K. Sakaue, K. Kadowaki, M. Akashi, *Adv. Healthc. Mater.* **2**, 534 (2013).
24. X. Ma, X. Qu, W. Zhu, Y.S. Li, S. Yuan, H. Zhang, J. Liu, P. Wang, C.S.E. Lai, F. Zanella, G.S. Feng, *Proc. Natl. Acad. Sci.* **113**, 2206 (2016).
25. R. Booth, H. Kim, *Lab Chip* **12**, 1784 (2012).
26. R. Lozano, L. Stevens, B.C. Thompson, K.J. Gilmore, R. Gorkin, E.M. Stewart, M. in het Panhuis, M. Romero-Ortega, G.G. Wallace, *Biomaterials* **67**, 264 (2015).
27. L. Horváth, Y. Umehara, C. Jud, F. Blank, A. Petri-Fink, B. Rothen-Rutishauser, *Sci. Rep.* **5**, 7974 (2015).
28. X. Wang, D.T. Phan, A. Sobrino, S.C. George, C.C. Hughes, A.P. Lee, *Lab Chip* **16**, 282 (2016).
29. V.K. Lee, A.M. Lanzi, H. Ngo, S.S. Yoo, P.A. Vincent, G. Dai, *Cell. Mol. Bioeng.* **7**, 460 (2014).
30. D.B. Kolesky, K.A. Homan, M.A. Skylar-Scott, J.A. Lewis, *Proc. Natl. Acad. Sci.* **113**, 3179 (2016).
31. J.U. Lind, T.A. Busbee, A.D. Valentine, F.S. Pasqualini, H. Yuan, M. Yadid, S.J. Park, A. Kotikian, A.P. Nesmith, P.H. Campbell, J.J. Vlassak, J.A. Lewis, K.K. Parker, *Nat. Mater.* **16**, 303 (2016).
32. F. Zheng, F. Fu, Y. Cheng, C. Wang, Y. Zhao, Z. Gu, *Small* **12**, 2253 (2016).
33. Y. Shin, S. Han, J.S. Jeon, K. Yamamoto, I.K. Zervantonakis, R. Sudo, R.D. Kamm, S. Chung, *Nat. Protoc.* **7**, 1247 (2012).
34. R.L. Truby, J.A. Lewis, *Nature* **540**, 371 (2016).
35. J.S. Miller, K.R. Stevens, M.T. Yang, B.M. Baker, D.H.T. Nguyen, D.M. Cohen, E. Toro, A.A. Chen, P.A. Galie, X. Yu, R. Chaturvedi, *Nat. Mater.* **11**, 768 (2012).
36. H.W. Kang, S.J. Lee, I.K. Ko, C. Kengla, J.J. Yoo, A. Atala, *Nat. Biotechnol.* **34**, 312 (2016).
37. D.B. Kolesky, R.L. Truby, A. Gladman, T.A. Busbee, K.A. Homan, J.A. Lewis, *Adv. Mater.* **26**, 3124 (2014).
38. K. Hölzl, S. Lin, L. Tytgat, S. Van Vlierberghe, L. Gu, A. Ovsianikov, *Biofabrication* **8**, 32002 (2016).
39. A. Arslan-Yildiz, R. El Assal, P. Chen, S. Guven, F. Inci, U. Demirci, *Biofabrication* **8**, 014103 (2016).
40. T.J. Hinton, Q. Jallerat, R.N. Palchesko, J.H. Park, M.S. Grodzicki, H.J. Shue, M.H. Ramadan, A.R. Hudson, A.W. Feinberg, *Sci. Adv.* **1** (9), e1500758 (2015).
41. S. Ahn, H. Lee, G. Kim, *Carbohydr. Polym.* **98**, 936 (2013).
42. X. Li, Z. Li, L. Wang, G. Ma, F. Meng, R.H. Pritchard, E.L. Gill, Y. Liu, Y.Y.S. Huang, *ACS Appl. Mater. Interfaces* **8**, 32120 (2016).
43. W. Wang, Y. Huang, M. Grujicic, D.B. Chrisey, *J. Manuf. Sci. Eng.* **130**, 21012 (2008). □

....

Yan Yan Shery Huang has been an assistant professor of bioengineering, in the Department of Engineering at the University of Cambridge, UK, since 2013. She obtained her PhD degree in physics in 2011 from the University of Cambridge. She was a joint Oppenheimer Research Fellow and a Homerton College Junior Researcher. Her research focuses on translational bioengineering research, 3D bioprinting/biomicrofabrication, and developing biomimetic organ-on-chips for high-throughput drug testing. Huang can be reached by email at yysh2cam@gmail.com.

....

Duo Zhang is a doctoral candidate in the Department of Engineering at the University of Cambridge, UK. He earned his BEng degree in electronics engineering from The University of Hong Kong in 2013, and received a China Scholarship Council scholarship for his graduate study. His research interests focus on 3D biofabrication techniques and development of *in vitro* mimetic tumor models for characterizing tumor–host interactions. Zhang can be reached by email at dz301@cam.ac.uk.

....

Ye Liu is a doctoral candidate in the Department of Engineering at the University of Cambridge, UK. She received her BEng degree in biomedical engineering and her MSc degree in biochemistry from Xi'an Jiaotong University, China, and a MEng degree from École Centrale de Lille, France. She is funded by the Schlumberger Foundation and Trinity College Cambridge. Her research focuses on understanding and reproducing the microenvironment of human stem cells. Liu can be reached by email at yl558@cam.ac.uk.

www.mrs.org/social-media

2017 MRS® FALL MEETING & EXHIBIT

Calling All Early-Stage Materials Innovators!

Showcase Your Technology…Connect with Investors & Industry Professionals

iMatSci Innovator Showcase

2017 MRS Fall Meeting & Exhibit
Hynes Convention Center | Boston, Massachusetts
Monday, November 27—Tuesday, November 28

Submission Deadline: September 1, 2017

iMatSci Innovator Showcase offers early-stage materials innovators a unique opportunity to meet and interact with industry and R&D leaders and early-stage investors to accelerate the adoption of new materials technologies for real-world applications. By participating, innovators will have the opportunity to:

- **Demonstrate** the practical applications of their materials-based technologies
- **Interact** with experienced technology investors
- **Network** with industry R&D leaders
- **Position** themselves for potential collaborators
- **Win** cash awards for best innovations as determined by Meeting attendees and a panel of judges

Why Get Involved?

Each innovator will be provided with exhibit space at the Hynes Convention Center Hub to present his/her technology or products using various forms of media such as tabletop demonstrations, videos and prototypes. This is not a poster session! Demonstrations will be judged by experienced technology investors and industry professionals.

By participating in iMatSci, innovators will be granted access to:

- **The Chemical Angel Network (CAN) Meeting,** with Fortune 100 investors; an opportunity to have their innovations reviewed by potential funders and for the top three selected innovators to pitch their ideas at the on-site CAN meeting

- **A full day of workshops, seminars and panel discussions,** with topics specifically targeted at the success of early-stage innovators

- **One-on-one meeting space for interaction with potential partners,** investors and collaborators

- **Exclusive networking events,** Q&A sessions and receptions

- **Exhibit Space** to showcase and pitch their innovations to investors, strategic partners and industry technology scouts

www.mrs.org/fall-2017-imatsci-submission

How to Participate

To participate, innovators should be:

- Interested in commercializing their technologies
- Able to propose a value proposition for their technologies
- Able to effectively demonstrate the commercial applications of their technologies
- Actively seeking partners, funding and/or paths for commercialization

Online applications will be accepted through **September 1, 2017,** and must be submitted through the iMatSci portal at **www.mrs.org/fall-2017-imatsci-submission.**

For further details about submission guidelines, innovator packages, judging/selection criteria and more, check out the complete iMatSci website at **www.mrs.org/imatsci.**

For more information, please contact:

Natalie Larocco
Materials Research Society
larocco@mrs.org
www.mrs.org

" My experience at iMatSci was invaluable. Few opportunities can match what iMatSci provides by allowing innovators to meet with other entrepreneurs to discuss their technology, pathways for funding, and strategies for commercialization. It was a richly stimulating experience."

–C. Wyatt Shields IV, iMatSci Innovator, Encapsio LLC; Research Triangle MRSEC Fellow

MRS Innovation ConneXions
Connecting People and Ideas